Post-earnings recap
Reported
Thu, Aug 1, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin's earnings report indicates a significant miss on EPS, which reflects ongoing challenges in profitability. Despite this, the stock rose by 2.12%, likely driven by investor optimism about the company's pipeline and future growth potential. The lack of revenue guidance may contribute to uncertainty among investors moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | -430.34% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future earnings due to ongoing investments in research and development. They emphasized the importance of their pipeline products.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on ongoing clinical trials and product development.